pharma manufacturing

‘Rejuvenated’ pharma manufacturing set for 2016 comeback

pharmafile | January 4, 2016 | News story | Manufacturing and Production, Sales and Marketing Employment, industry, manufacturing, patent cliff, pharma, production 

The pharma industry has been singled out for its strong performance in 2015, in a report which says manufacturing in the sector helped to offset the weaknesses in other areas of the UK economy.

An analysis by EEF, an organisation that represents over 20,000 manufacturers in the UK and economic forecasters Oxford Economics, heaped praise on the pharma industry for taking a step forward while the wider manufacturing industry saw a ‘significant weakening’ in 2015.

“Looking at the sector as a whole, growth has disappointed in 2015 and we’ve seen overall confidence levels tail off through the year,” says EEF chief economist Lee Hopley. But manufacturing in the pharma industry ‘staged a comeback’ in 2015, and the analysis forecasts that the growth seen in the ‘rejuvenated’ pharma manufacturing industry will continue into 2016.

“It’s not all doom and gloom,” the report finds. “The rejuvenation of the pharmaceutical industry providing reasons for cheer in UK manufacturing. Prospects for the chemicals and pharmaceuticals industries are looking positive, with a drop in input costs and the end pf the patent cliff for the latter, driving growth in these sectors.

Advertisement

“After five consecutive years of contraction, the sector is finally coming off the patent cliff. Fundamentals are now looking strong for the industry, with ongoing acquisitions and pipelines for new products coming on stream. We expect the sector to grow by 1.0% this year and we see upside risks to our forecasts for robust growth of 2.2% in 2016.”

The report also predicts that employment in the pharma manufacturing sector will also increase in 2016, by 1.5% – having fallen by 3.1% in 2015. The sector is one of only three that is forecast to see growth in employment rates in the UK in 2016.

Lilian Anekwe

Related Content

drug-trials

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence

LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

CARBOGEN AMCIS manufacturing license advances services in China

Swiss pharma manufacturing company, CARBOGEN AMCIS, has announced that its facility in Shanghai, China, has …

Meribel Pharma Solutions launches to take pharma services to new heights

Meribel Pharma Solutions, a new mid-sized contract development and manufacturing organisation (CDMO), has officially launched …

The Gateway to Local Adoption Series

Latest content